Holobiome
Innovative therapies from the human microbiome to address nervous system disorders and major health challenges.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $9.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Holobiome is a pioneering biotech company focused on developing groundbreaking therapies derived from the human microbiome. Founded by research scientists from Northeastern University, the company aims to unlock the potential of gut microbes to improve global health. Holobiome operates in the healthcare and biotechnology market, primarily serving patients with nervous system disorders and other significant health issues. The company's business model revolves around rigorous scientific research and development, translating emerging microbiome science into practical medical solutions. Revenue is generated through the development and commercialization of these innovative therapies. Holobiome is driven by a commitment to patient care and scientific excellence, positioning itself as a leader in microbiome-based treatments.
Keywords: microbiome, biotech, therapies, nervous system, health, research, innovation, commercialization, patient care, scientific excellence.